Alphatec (NASDAQ:ATEC) Sets New 12-Month High - Time to Buy?

Key Points

• Alphatec Holdings, Inc. reached a new **52-week high** of $13.89, with significant trading volume of **12,995,953 shares**.
• Brokerages reaffirmed a **"buy" rating** for the stock, with price targets ranging from **$15.00 to $20.00**, reflecting strong growth expectations.
• The company reported a **22.2% increase in revenue** year-over-year, though it missed earnings estimates with an EPS of **($0.35)** for the latest quarter.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) reached a new 52-week high on Saturday . The company traded as high as $13.89 and last traded at $13.77, with a volume of 12995953 shares. The stock had previously closed at $10.58.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Barclays restated an "overweight" rating and issued a $22.00 price target (up previously from $21.00) on shares of Alphatec in a report on Monday. Needham & Company LLC reissued a "buy" rating and set a $16.00 price target on shares of Alphatec in a research report on Friday, May 2nd. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday, June 16th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Alphatec has a consensus rating of "Moderate Buy" and an average target price of $18.50.

Alphatec Price Performance

The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The company has a 50-day simple moving average of $11.47 and a two-hundred day simple moving average of $11.20. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -13.45 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The company had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. During the same quarter in the prior year, the business posted ($0.29) earnings per share. The company's revenue for the quarter was up 27.5% compared to the same quarter last year. On average, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Insider Transactions at Alphatec

In other news, EVP Craig E. Hunsaker sold 186,122 shares of the stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $12.34, for a total value of $2,296,745.48. Following the completion of the transaction, the executive vice president owned 1,463,896 shares of the company's stock, valued at approximately $18,064,476.64. This represents a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the transaction, the general counsel directly owned 438,331 shares of the company's stock, valued at approximately $6,535,515.21. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 389,121 shares of company stock valued at $4,929,887. 22.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATEC. Raymond James Financial Inc. purchased a new stake in shares of Alphatec during the 4th quarter worth about $358,000. Commonwealth Equity Services LLC grew its holdings in shares of Alphatec by 55.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 36,929 shares of the medical technology company's stock worth $339,000 after purchasing an additional 13,246 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Alphatec during the 4th quarter worth approximately $228,000. LPL Financial LLC lifted its position in shares of Alphatec by 19.9% during the 4th quarter. LPL Financial LLC now owns 413,235 shares of the medical technology company's stock worth $3,793,000 after buying an additional 68,516 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Alphatec by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after buying an additional 47,797 shares during the period. Institutional investors own 66.35% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.